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Abstract 105 
Background: Substantial evidence supports an association between use of menopausal 106 
hormone therapy and increased colorectal cancer (CRC) risk, indicating a role of exogenous 107 
sex hormones in CRC development. However, findings on endogenous estrogen exposure 108 
and CRC are inconsistent.  109 
Methods: We used a Mendelian randomization approach to test for a causal effect of age at 110 
menarche and age at menopause as surrogates for endogenous estrogen exposure on CRC 111 
risk. Weighted genetic risk scores based on 358 single nucleotide polymorphisms associated 112 
with age at menarche and 51 single nucleotide polymorphisms associated with age at 113 
menopause were used to estimate the association with CRC risk using logistic regression in 114 
12 944 women diagnosed with CRC and 10 741 women without CRC from three consortia. 115 
Sensitivity analyses were conducted to address pleiotropy and possible confounding by body 116 
mass index.  117 
Results: Genetic risk scores for age at menarche (odds ratio per year 0.98, 95% confidence 118 
interval: 0.95-1.02) and age at menopause (odds ratio 0.98, 95% confidence interval: 0.94-119 
1.01) were not significantly associated with CRC risk. The sensitivity analyses yielded 120 
similar results.  121 
Conclusion: Our study does not support a causal relationship between genetic risk scores for 122 
age at menarche and age at menopause and CRC risk. 123 
 124 
Keywords: BMI, egger regression, endogenous estrogen, hormonal factors, menstrual, 125 
polygenic risk score, reproductive factor, sex hormone, weighted median 126 
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BACKGROUND 127 
Colorectal cancer (CRC) is the third most common cancer worldwide and incidence rates are 128 
higher in men than in women.1 The sex-specific difference might be partly attributed to 129 
differential exposure to sex-hormones, especially estrogen.2 This hypothesis is partially 130 
supported by epidemiologic studies as well as a recent meta-analysis out of four randomized 131 
controlled trials, eight cohort and eight case-control studies, which have shown that use of 132 
exogenous sex hormones in the form of combined estrogen-progestogen menopausal 133 
hormone therapy (MHT) is inversely associated with the risk of CRC.3, 4 134 
Epidemiologic studies examining reproductive factors such as age at menarche and age at 135 
menopause with CRC risk have reported inconsistent results.5-7 A meta-analysis 136 
summarizing evidence based on 22 studies published by Li et al. did not find a significant 137 
association between age at menarche and CRC risk.8 In a large prospective cohort of the NIH 138 
American Association of Retired Persons (AARP) Diet and Health Study with more than 139 
214,000 postmenopausal women, an inverse association between age at menarche and CRC 140 
risk was observed for women without a history of MHT use, whereas increasing age at 141 
menopause was associated with higher CRC risk.9 It is possible that the inconsistency in 142 
results is due to recall bias or to improper adjustment for confounders, which are inherent 143 
limitations of observational studies. The Mendelian randomization (MR) approach10 uses 144 
genetic variants as instrumental variables to test for the causal effect of an exposure risk 145 
factor on an outcome. Since the genetic variants in offspring are randomly distributed at 146 
conception independent of environmental factors given parental genotypes, confounding and 147 
reverse causation are less likely to occur in MR analyses. For genetic variants to function as 148 
valid instrumental variables in MR analyses, three assumptions have to be met: 1) the genetic 149 
variants have to be associated with the exposure risk factor; 2) the variants are not associated 150 
with any confounding variables of the exposure-outcome association; and 3) the variants are 151 
unrelated to the outcome except through the risk factor of interest.11, 12 Using variants 152 
associated with age at menarche and age at menopause instead of self-reported measure of 153 
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the risk factors themselves, this approach can help to avoid issues of confounding, recall bias 154 
and reverse causation. Evidence from MHT use suggests that more exposure to estrogen 155 
reduces risk of CRC.3, 4, 13 Estrogen exerts its effects in colon cells predominantly through the 156 
nuclear receptor estrogen-receptor β (ERβ),14, 15 which has mainly anti-proliferative effects16 157 
and its expression is inversely related to cancer stage, tumor extent and mortality.17, 18 Longer 158 
use of MHT appears to be associated with high ERβ expression in tumors.19 If similar 159 
mechanisms hold then longer endogenous estrogen exposure (through earlier age at 160 
menarche and/or later age at menopause) would reduce CRC risk as well. To test this 161 
hypothesis, we conducted a MR analysis using summary data for single nucleotide 162 
polymorphisms (SNPs) known to be associated with age at menarche and age at menopause 163 
from prior studies as well as using individual level data of three consortia. 164 
MATERIALS AND METHODS 165 
Study population. Epidemiological and genetic data were derived from 26 studies 166 
participating in three large consortia of CRC, the Genetics and Epidemiology of Colorectal 167 
Cancer Consortium (GECCO)20 (5 386 cases and 5 696 controls), the Colon Cancer Family 168 
Registry (CCFR)21 (1 678 cases and 1 188 controls) and the Colorectal Cancer 169 
Transdisciplinary (CORECT) Consortium22 (5 880 cases and 3 857 controls) (see 170 
Supplementary Tables 1 and 2). Different centers of CCFR participated as individual studies 171 
in GECCO and/or CORECT, and therefore were analyzed as such. Any participant overlap 172 
between the three consortia was excluded. In total, 12 944 female colorectal cancer cases and 173 
10 741 female controls, both of European ancestry were included. All participants provided 174 
written, informed consent and studies were approved by their respective institutional review 175 
boards. Women with incident invasive colorectal adenocarcinoma (International 176 
Classification of Disease Code, 9th revision (ICD-9), codes 153-154) were included as cases. 177 
Data on demographic factors and lifestyle were collected using in-person interviews or self-178 
completed questionnaires. Data harmonization was done centrally as previously described.23 179 
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Self-reported data for age at menarche and age at menopause have not been harmonized and 180 
therefore could not be used.  181 
Genotype data and imputation. Genotype information was available for all included 182 
studies. Details on genotyping, quality assurance and imputation are included in the 183 
Supplementary Information. In short, SNPs were excluded based on call rate (<98% 184 
GECCO; <95% in CORECT), Hardy-Weinberg equilibrium in controls (P<1x10-4) or low 185 
minor allele frequency (≤1%). Participants received a value of 0, 1, or 2 for carrying 0 (wild-186 
type homozygous), 1 (heterozygous) or 2 (homozygous for the risk allele) alleles associated 187 
with higher age at menarche/age at menopause for each SNP. For imputed SNPs, participants 188 
were assigned continuous values between 0 and 2.  189 
Calculation of genetic risk scores. Two recent genome-wide association studies 190 
conducted by the REPROGEN consortium (Reproductive Genetics Consortium) involving 191 
up to ~370 000 women for the study on age at menarche and up to 69 360 women for the 192 
study on age at menopause identified 389 genetic variants associated with age at menarche24 193 
and 54 SNPs associated with age at natural menopause25 at a genome-wide significance level 194 
(i.e., P<5x10-8). Of the reported 389 genetic variants for age at menarche, 12 variants on sex 195 
chromosomes (which were not available in our datasets) were excluded. For further 42 196 
missing variants, we used proxy SNPs in strong linkage disequilibrium (R²>0.8, median 197 
R²=0.985, R² range: 0.83-1.00) with effect alleles harmonized to reflect increase in age at 198 
menarche. Seven variants were excluded because no proxy was found. We checked for 199 
correlations between individual SNPs and excluded 12 correlated SNPs (R²>0.01) (always 200 
the SNP with higher P-value for association with age at menarche was dropped). So data 201 
were available for 358 SNPs for this analysis (mean imputation quality score=0.97) 202 
(Supplementary Table 5). For age at menopause, three correlated SNPs (R²>0.01) were 203 
excluded. All remaining 51 SNPs for age at menopause were available in the datasets (mean 204 
imputation quality score=0.98) (Supplementary Table 6). The genotype data described were 205 
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used to construct genetic risk scores (GRS) as instrumental variables for age at menarche and 206 
age at menopause, respectively.  207 
The GRS for the kth women is calculated by the sum of the number of risk increasing alleles 208 
carried (G) (imputed allele doses) for each SNP weighted by the reported beta-coefficient (β) 209 
for association with age at menarche and age at menopause.24, 25 210 
Age at menarche   211 
GRS݇ = ෍ ߚ݊ ܩ݇݊
358
݊=1
 
 212 
Age at menopause   213 
GRS݇ = ෍ ߚ݊ ܩ݇݊
51
݊=1
 
 214 
As risk scores themselves do not have meaningful units, we scaled the risk scores in terms of 215 
age in years. In this way resulting odds ratios (OR) can be interpreted as the relative change 216 
in CRC risk per year older age at menarche/age at menopause. Scaling was done by dividing 217 
the GRS by regression coefficients of a linear regression of GRS on self-reported age at 218 
menarche (beta= 0.57) or age at menopause (beta=0.98). These regression coefficients were 219 
obtained using the DACHS (Darmkrebs: Chancen der Verhütung durch Screening) study 220 
(853 control women) and the WHI (Womens’ Health Initiative) study (1 492 control women) 221 
for which self-reported data on age at menarche were available and regression coefficients of 222 
the two studies were combined using meta-analysis.  223 
An additional GRS as a surrogate for total lifetime exposure to endogenous estrogen was 224 
calculated as the sum of the scaled risk scores for age at menarche and age at menopause.  225 
GRSݐ݅݉݁  ݌݁ݎ݅݋݀ = GRSܽ݃݁  ܽݐ  ݉݁݊ܽݎܿ ℎ݁ + GRSܽ݃݁ ܽݐ ݉݁݊݋݌ܽݑݏ݁  
 226 
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For this analysis, risk scores for age at menarche were calculated as the sum of the number 227 
of alleles associated with decreasing age at menarche and the number of alleles associated 228 
with increasing age at menopause. So the GRS for time period of estrogen exposure reflects 229 
higher risk for longer exposure to endogenous estrogen. For this score, four SNPs 230 
(rs3136269, rs11031040, rs537244, rs4303811) were excluded due to high linkage 231 
disequilibrium (R²>0.01) between age at menarche and age at menopause SNPs. 232 
 233 
Statistical analysis.  234 
Validating MR assumptions 235 
The first assumption of MR regarding instrumental variable strength (i.e. association 236 
between the genetic variants and the exposure risk factor) was verified by calculating the F-237 
statistic out of F= (R²(n-K-1))/((1-R²)K)), where R² refers to the variance explained by the 238 
instrumental variable,24, 25 K indicates the number of instrumental variables and n stands for 239 
the sample size.26 An F-statistic >10 suggests that the genetic instrument is sufficiently 240 
strong.27 To evaluate the second assumption of MR (i.e. no association between genetic 241 
variants and potential confounders), we tested associations between GRS for age at 242 
menarche/age at menopause and the following risk factors for CRC: smoking status 243 
(ever/never), family history of CRC, education/educational level, ever aspirin/NSAID use (at 244 
least once per month for more than one year), body mass index (BMI) (continuous), 245 
menopausal hormone therapy (estrogen/progestin combined and estrogen alone), using linear 246 
regression for continuous variables and logistic/multinomial logistic regression for 247 
categorical variables in a subset of the studies with available data (n=6 285 controls). To 248 
address the third assumption of MR i.e. to assess the presence of pleiotropy, we applied the 249 
MR-Egger method.28 MR-Egger relies on the InSIDE assumption (Instrument Strength 250 
Independent of Direct Effect), which is the assumption that the pleiotropic effects of the 251 
genetic variants are not correlated with the effects of genetic variants on the risk factors. 252 
MR-Egger uses an inverse-variance weighted estimator and by plotting the SNP`s effect on 253 
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the exposure against its effect on the outcome, the intercept term of MR-Egger provides a 254 
test for directional pleiotropy, i.e. the average effect of pleiotropy is non-zero, across all 255 
genetic variants used. If the average pleiotropic effect of all variants is zero and the InSide 256 
assumption is satisfied, pleiotropy is “balanced” and will not be detected. If the intercept 257 
differs from zero, it suggests horizontal pleiotropy, which means that some genetic variants 258 
affect the outcome through a pathway different from the exposure of interest. For visual 259 
inspection of pleiotropy, we used funnel plots of each SNPs ratio estimate against its 260 
precision (1/standard error of the ratio estimate).29, 30 Any deviation from symmetry would 261 
suggest pleiotropy. 262 
Estimation of Causal Effect 263 
GRS based analyses 264 
We examined the association between GRS and CRC risk using logistic regression models 265 
adjusted for study, age as well as principal components (PCs) of genetic ancestry (three PCs 266 
were used for GECCO and 10 PCs were used for CORECT), to account for potential 267 
population stratification. Summary results for GECCO and CORECT were derived using 268 
fixed-effects meta-analysis assuming that the included studies share a common effect size. 269 
As there are indications for differential associations of age at menarche with CRC risk 270 
according to menopausal hormone use,9, 31 stratified analyses by menopausal hormone 271 
therapy were performed (only in GECCO where harmonized data were available). Additional 272 
stratified analyses were performed according to menopausal status (for age at menarche), 273 
combined menopausal estrogen or progesterone therapy, estrogen therapy alone, and BMI 274 
categories in kg/m² (BMI<18.5: underweight, 18.5–24.9: normal weight, 25-30: overweight, 275 
>30: obese) (only for age at menopause). Due to reported differences in risk between colon 276 
and rectal cancer associated with hormone use,32, 33 we also conducted site-specific analyses 277 
for 4 037 female colon cancer cases and 1 184 rectal cancer cases in GECCO. Power 278 
calculations were conducted to estimate the magnitude of effects detectable with our study 279 
size assuming 5% alpha level and an R² of 0.069 for age at menarche and R² of 0.057 for age 280 
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at menopause, which corresponds to the variance in age at menarche/age at menopause 281 
explained by the SNPs used for this analyses.34 282 
It is known that BMI in childhood is strongly associated with age at menarche35 and that 283 
some SNPs associated with age at menarche could also have pleiotropic effects e.g. are 284 
related to BMI as well.24 To address this issue and thereby also account for violations of the 285 
third MR assumption, we conducted further BMI-specific sensitivity analyses. We adjusted 286 
for BMI in the logistic regression analysis using a weighted GRS for BMI comprising 77 287 
SNPs previously reported to be associated with BMI at a genome-wide significance level in 288 
European subjects.36 For the second sensitivity analysis, we identified age at menarche SNPs 289 
showing pleiotropy by testing the association of these SNPs with BMI in a subset of our 290 
sample (n=5 832 cases/6 285 controls) and found 29 SNPs to be associated with BMI at 291 
nominal significance (P value<0.05). Two further SNPs overlapped with reported BMI-292 
SNPs36 and eleven more SNPs were in high linkage disequilibrium (R²>0.1) with BMI SNPs. 293 
A restricted GRS for age at menarche excluding the 42 BMI-associated SNPs (n=316 SNPs) 294 
was constructed and then assessed for association with CRC risk. For the analysis of lifetime 295 
estrogen-exposure we also generated a restricted risk score excluding the same 42 BMI-296 
associated SNPs.  297 
Two-sample MR analyses 298 
We performed two-sample MR analyses as sensitivity analyses using published summary 299 
statistics for SNP-exposure associations (age at menarche24/age at menopause25), SNP 300 
outcome associations were estimated in GECCO/CORECT (Supplementary Tables 8 and 9 301 
for age at menarche/menopause-SNPs respectively). We applied the weighted median 302 
estimator approach, which is robust against violations due to pleiotropic SNPs even when up 303 
to 50% of the genetic instruments are invalid.37 For this approach, we used SNP-exposure 304 
and SNP-outcome associations to build ratio estimates for each SNP. These estimates were 305 
ordered and weighted by the inverse of their variance. Bootstrapped standard errors were 306 
calculated and used for construction of 95% confidence intervals (CI). Furthermore, we 307 
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assessed the slope of MR-Egger regression (see section on validation of MR assumptions) 308 
which yields a pleiotropy-adjusted estimate of the true causal effect.28  309 
All analyses were conducted using R version 3.2.2 (R Foundation for Statistical Computing, 310 
Vienna, Austria). For supplementary figures, we used the R packages “Mendelian 311 
Randomization”38 and “ggplot2”. 312 
RESULTS 313 
The assessment of the MR assumptions indicated that our instrumental variables for age at 314 
menarche and for age at menopause were both strong instruments (F-statistic for age at 315 
menarche=1 755, R²=0.06924; F-statistic for age at menopause=1 431, R²=0.05725. Secondly, 316 
we did not find significant associations between the GRS for age at menarche and CRC risk 317 
factors, including smoking, family history of cancer, education, aspirin/NSAID use, 318 
estrogen/progestin therapy, estrogen alone therapy, with the exception of BMI, which 319 
showed a significant association (Supplementary Table 3). Similarly, there was no 320 
association of the GRS for age at menopause with any of the tested risk factors 321 
(Supplementary Table 3). Table 1 shows the results of the MR analyses for age at menarche, 322 
age at menopause and lifetime estrogen exposure with CRC risk. Yearly increment in GRS 323 
for age at menarche was associated with CRC risk with an OR of 0.98 (95% CI: 0.95-1.02). 324 
Sensitivity analyses adjusting for BMI using a GRS yielded similar results for age at 325 
menarche (OR 0.99 per year, 95% CI: 0.95-1.02). Further sensitivity analysis using restricted 326 
risk scores for age at menarche (by excluding 42 BMI-associated SNPs) showed similar 327 
effect sizes for the association between age at menarche and CRC risk (OR 0.99 per year, 328 
95% CI: 0.95-1.03). We also did not find evidence to support a causal association with risk 329 
of CRC for age at menopause (OR 0.98 per year, 95% CI: 0.94-1.01) or for lifetime estrogen 330 
exposure (OR 0.99 per year, 95% CI: 0.97-1.02) using GRS-based analyses.  331 
Results of the weighted median estimator approach also did not indicate causal association 332 
between age at menarche (OR per year 1.00, 95% CI: 0.90-1.11), age at menopause (OR per 333 
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year 1.00, 95% CI: 0.95-1.05) or lifetime estrogen-exposure (OR per year 1.00, 95% CI: 334 
0.95-1.05) with CRC risk. 335 
The pleiotropy adjusted MR estimate (OR) derived from the slope of Egger regression was 336 
0.99 (95% CI: 0.83-1.17) for age at menarche, 1.02 (95% CI: 0.94-1.10) for age at 337 
menopause and 0.97 (95% CI: 0.91-1.01) for lifetime estrogen-exposure (details of results 338 
per GECCO and CORECT consortium in Supplementary Table 7). The intercept term from 339 
MR-Egger regression was centered at the origin for age at menarche (intercept term -0.0008, 340 
95% CI: -0.007-0.005, P value 0.80) and age at menopause (intercept term -0.009, 95% CI: -341 
0.023-0.006, P value 0.23) suggesting absence of strong directional pleiotropy 342 
(Supplementary Figure 1 and 2). Also the funnel plots for age at menarche and age at 343 
menopause appear to be generally symmetrical and therefore do not suggest presence of 344 
pleiotropy (Supplementary Figure 3 and 4). Table 2 shows stratified analyses for the 345 
association of GRS for age at menarche and CRC risk by menopausal status, combined 346 
estrogen/progesterone therapy and estrogen alone therapy as well as cancer site based on 347 
GECCO data. None of these factors modified substantially the association between age at 348 
menarche and CRC risk. The site specific analysis showed no evidence for a difference in 349 
association between colon cancer (OR 0.97 per year, 95% CI: 0.91-1.02) and rectal cancer 350 
(OR 1.04 per year, 95% CI: 0.95-1.14). The analyses for age at menopause stratified by 351 
combined estrogen/progesterone therapy, estrogen alone therapy, BMI and cancer site did not 352 
yield evidence for effect heterogeneity (Table 3). Power calculation shows that our study had 353 
> 80 % power to detect an OR of 0.85 per standard deviation change in exposure variable 354 
(1.5 years for age at menarche, 4.8 years for age at menopause) but only around 50% power 355 
for an OR of 0.90 (Supplementary Table 4). 356 
DISCUSSION 357 
In this large MR study we aimed to clarify the inconsistent findings from observational 358 
studies regarding the association of age at menarche and age at menopause with CRC risk 359 
and thereby the role of endogenous estrogen exposure. We investigated the association of 360 
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GRS for age at menarche and age at menopause as surrogates for endogenous estrogen 361 
exposure on CRC risk. Our results do not support an association between GRS for age at 362 
menarche and age at menopause and CRC risk, which under MR assumptions can be 363 
interpreted as absence of a causal effect.  364 
In line with the findings of our study, several prospective studies and one meta-analysis 365 
reported no association6, 8, 39 between self-reported age at menarche and CRC risk, although 366 
some studies found an inverse association.5, 9 Two more recent prospective studies reported 367 
inverse associations with CRC risk for age at menarche only among never users of any MHT. 368 
In never users of hormone therapy, Zervoudakis et al. reported a hazard ratio of 0.73 (95% 369 
CI: 0.57-0.94) for age at menarche (>15 vs. 11-12 years) in association with risk of CRC9 370 
and Murphy et al. found a hazard ratio of 0.72 (95% CI: 0.54-0.96) for age at menarche (>15 371 
vs. 11-12 years).31 We therefore assessed the association of GRS for age at menarche with 372 
CRC risk stratified by ever/never use of MHT, separately for combined estrogen-373 
progesterone therapy and for estrogen monotherapy. No difference in the association 374 
according to either combined estrogen-progesterone therapy or estrogen-alone therapy was 375 
found.  376 
Higher BMI in childhood is associated with earlier age at menarche24, 35 and also with a 377 
higher risk for CRC.40 Therefore we conducted BMI-specific sensitivity analyses to account 378 
for violations of the MR assumptions by confounding and pleiotropy. Due to a strong 379 
association between childhood/adolescent BMI and adult BMI41 and also a high concordance 380 
between adolescent and adult BMI-SNPs,42 we accounted for adult BMI in sensitivity 381 
analyses. The effect sizes observed in the sensitivity analysis (by excluding BMI-associated 382 
SNPs and by adjustment using a GRS for BMI) were slightly smaller compared to results of 383 
the main analysis, which suggests that some of the effect was confounded by BMI. Our 384 
restricted risk-score might not be totally BMI-unrelated, considering that Day et al.24 found 385 
age at menarche variants that appear unrelated to BMI at a nominal level in their sample to 386 
be still BMI associated collectively (P=4.2x10-9). Because of this strong interrelationship 387 
between age at menarche and BMI it is difficult to separate the SNPs into BMI-related and 388 
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BMI-unrelated variants. So our adjustment of the analysis by GRS-BMI might more 389 
effectively control for BMI. Thus, any observed inverse relationship between age at 390 
menarche and CRC risk in previous observational studies could have been due to inadequate 391 
control of confounding by higher BMI in childhood.  392 
For age at menopause, results of observational studies on the association with CRC risk have 393 
also been inconclusive. The large NIH-AARP study observed a statistically significant 394 
elevated risk for higher age at menopause in postmenopausal women (≥55 vs < 40; HR 1.50, 395 
95% CI: 1.23, 1.83),9 whereas most other studies reported null associations.6, 31, 39 396 
Corresponding to the lack of association with age at menarche and age at menopause, the 397 
GRS for the reproductive period as indicator for the lifetime estrogen exposure was also not 398 
significantly associated to CRC risk. Additional adjustment of that analysis by education, 399 
family history of CRC, ever regular aspirin use, MHT usage, BMI and smoking did not 400 
substantially change the results (Supplementary Table 10). This is compatible with the 401 
observation of no association between the reproductive period (≥ 36 years vs. ≤ 30 years) 402 
and CRC risk in a prospective observational study conducted in Japan43. The GRS for 403 
lifetime for endogenous estrogen exposure, which we constructed, does not account for other 404 
factors like parity or breast feeding, which influence overall estrogen exposure, however, 405 
these factors have not been associated with CRC risk. 406 
Results of prospective studies that investigated the association between serum levels of 407 
endogenous estrogens and CRC risk have also been inconsistent. One study reported a 408 
positive association between circulating estradiol and CRC risk,44 another study observed an 409 
inverse relationship45 while most other studies found no associations.46-48 There are reports 410 
that earlier age at menarche is associated with higher estrogen levels.49, 50 So estrogen levels 411 
could also be a possible link between age at menarche and CRC risk. Due to the inconsistent 412 
results of these reports, further studies are needed to clarify these associations.  413 
On the other hand, observational studies reported that exogenous estrogen exposure by MHT 414 
mainly in the form of combined estrogen-progestogen was associated with a reduced risk for 415 
CRC.13, 51 The Womens`s Health Initiative Clinical Trial (WHI-CT) reported no effect of 416 
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estrogen-alone therapy,52, 53 and a significant risk reduction for the association of estrogen 417 
plus progestin vs. placebo and CRC risk,33 which was suggested to have resulted from 418 
diagnostic delay instead of true risk reduction54. However, a recent meta-analysis which 419 
summarized results of four clinical trials including WHI-CT and 16 observational studies 420 
concluded that there is consistent evidence to support a protective effect of MHT on CRC 421 
risk.4 422 
Thus, it appears that exogenous and endogenous estrogens, which also vary in absolute 423 
amount of estrogen, may play different roles in the development of CRC, presumably by 424 
different mechanisms, which are not well understood. Estrogen acts in colon cells 425 
predominantly through ERβ,14, 15 which exerts proapoptotic and anti-proliferative effects in 426 
the colon16 and its expression is reduced in tumor tissue.17, 18 According to an in vivo study, 427 
estrogen treatment was associated with an increase in expression of ERβ in colon tissue,55 428 
supporting a mechanism by which MHT may affect CRC risk. There is also some evidence 429 
that the protective effect of MHT on CRC risk may vary by the expression status of ERβ. 430 
Two studies found that the magnitude of risk reduction by MHT was different between 431 
colorectal tumors with higher and with lower expression of ERβ.56, 57 It is possible that the 432 
effect of endogenous estrogens on CRC risk may be modulated by ERβ expression as well. 433 
Therefore, larger studies with data on expression of ERβ in colon tissue are warranted to 434 
assess whether the association of age at menarche/age at menopause and CRC risk differs by 435 
ERβ expression status. 436 
In this MR study, we aimed to use proxies for start and endpoint of endogenous estrogen 437 
exposure in women, specifically age at menarche/age at menopause, which themselves are 438 
complex traits influenced by many variants with only small effects on the trait. Although we 439 
did not see large pleiotropic effects using Egger regression, there might have been residual 440 
pleiotropy, which is difficult to exclude. Previous studies of age at menarche performed LD 441 
score regression using 123 SNPs associated with age at menarche and found, amongst others, 442 
genetic correlations with BMI, adult height or Type 2 diabetes. Residual pleiotropy related to 443 
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adult height or Type 2 diabetes, which have been reported to be associated with higher risk 444 
for CRC as well, cannot be fully excluded.58 In addition, Day et al. reported genetic 445 
correlations for the 54 age at menopause SNPs with adult obesity and other growth-related 446 
traits. The top menopause-SNPs were also associated with fasting glucose and were enriched 447 
in DNA repair pathways, yielding further sources of residual pleiotropy.25 Residual 448 
pleiotropy is a general limitation of MR, especially when exploring complex traits. When 449 
considering the recently published hypothesis of an omnigenic model of complex traits, 450 
coined „network pleiotropy“, essentially any regulatory variant in a trait-relevant cell-type 451 
can have some effect on the trait.59 This is because specific cell-types have specific 452 
regulatory networks, where any single variant could affect trait relevant genes, „core genes“, 453 
mediated through the same regulatory networks. So also for GWAS findings, it is highly 454 
likely that some genetic variants exhibit horizontal pleiotropy.60 As the selected age at 455 
menarche/age at menopause SNPs might also contribute tiny effects on further traits through 456 
network-pleiotropy, we cannot fully rule out pleiotropy. These limitations should be kept in 457 
mind and methods to explore the impact of such effects should be developed. That said, our 458 
sensitivity analyses especially Egger regression, did not indicate large pleiotropic effects.  459 
The second assumption of MR is that the IV is not associated with confounding factors of 460 
the observational association between age at menarche/menopause and CRC risk. We were 461 
able to exclude most risk factors for CRC (smoking, family history of CRC, education, 462 
aspirin use, MHT) as confounding variables except for BMI, which was accounted for using 463 
several sensitivity analyses. In addition, substantial overlap between datasets used for 464 
estimating SNP-exposure and SNP-outcome associations would bias results in the direction 465 
of the observational estimate. There was some overlap between the studies (see 466 
Supplementary Information on participant overlap) but unlikely to have substantially 467 
influenced the results. 468 
Strengths of our study include the large sample size, the availability of centrally harmonized 469 
data and the robustness of the instrumental variables. Power calculations showed that our 470 
study has limited power to detect weak effects. Therefore, we cannot exclude a weak 471 
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association of CRC with age at menarche or age at menopause. In summary, in our large MR 472 
study, evidence is limited for causal associations between age at menarche/age at menopause 473 
and CRC risk.  474 
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Table 1: Association between age at menarche/age at menopause and CRC risk using MR analyses and sensitivity analyses
Cases/Controls OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
12 944/10 741 0.98 0.95-1.02 0.99 0.95-1.02 0.99 0.95-1.03 0.99 0.83-1.17 1.00 0.90-1.11
12 944/10 741 0.98 0.94-1.01 NA NA NA NA 1.02 0.94-1.10 1.00 0.95-1.05
Abbreviations: BMI, body mass index; CCFR, colon cancer family registry; CI, confidence interval; CORECT, Colorectal Transdisciplinary study; GECCO, Genetics and Epidemiology of
Colorectal Cancer Consortium; GRS, genetic risk score; MR, Mendelian randomization; NA, not applicable;  OR, odds ratio per year, SNPs, single nucleotide polymorphisms; se, standard error.
a Logistic regression model adjusted for age, study and principal components of genetic ancestry;
b Meta-analyzed estimate of GECCO/CORECT datasets (CCFR centers participated in GECCO or CORECT and were analyzed as such);
c additionally adjusted for a GRS for BMI out of 77 reported SNPs for BMI 33;
d 42 BMI-associated SNPs were excluded from the age at menarche and time period of estrogen -exposure – risk scores;
e estimate derived from the slope of MR-Egger;
f estimates derived using summary statistics; se for calculation of CI obtained via bootstrapping.
2-sample MRf
0.97-1.02 0.99 0.97-1.010.99 0.97-1.02 0.99 0.95-1.05
MR-Eggerb,e
Weighted Median 
Estimatorb
GRS-based analyses
Adjusted by GRS-
BMIa,c
Restricted risk 
scorea,dMR estimate
a,b
Variable (per year)
Age at menarche
Age at menopause
Time period of 
hormone exposure 12 944/10 741 1.000.97 0.93-1.01
Table 2. Association of genetically predicted age at menarche with CRC risk according to subgroups, CCFR, GECCO Consortium
Subgroup N (cases/controls) ORa 95% CI P  value
All 5832/6285 0.97 0.92-1.02 0.20
   Premenopausal 545/621 0.95 0.80-1.12 0.54
   Postmenopausal 5263/5647 0.97 0.92-1.02 0.23
   No 3266/3490 0.96 0.90-1.03 0.24
   yes 593/807 0.98 0.85-1.14 0.82
   No 3120/3214 0.94 0.88-1.01 0.11
   yes 716/1088 1.04 0.91-1.19 0.55
Site
   Colon 4037/6285 0.97 0.91-1.02 0.26
   Rectum 1184/6285 1.04 0.95-1.14 0.36
Abbreviations: CCFR, colon cancer family registry; CI, confidence interval; GRS, genetic risk score; OR, odds ratio per year.
a all analyses adjusted for age, sex, study and principal components of genetic ancestry;
b P  value calculated using likelihood ratio tests comparing the model with and without interaction term;
c P  value for heterogeneity was obtained in case-only analysis of colon vs. rectal cancer.
Estrogen monotherapy
Menopausal status
Menopausal hormone therapy combined
0.25c
Heterogeneity P  valueb
0.69
0.17
0.94
Table 3. Association of genetically predicted age at menopause and CRC risk according to subgroups, CCFR, GECCO Consortium
N (cases/controls) ORa 95% CI P  value Heterogeneity P value b
All 5832/6285 0.99 0.95-1.03 0.56
   No 3266/3490 0.99 0.93-1.05 0.78 0.75
   Yes 593/807 0.96 0.85-1.10 0.58
   No 3120/3214 0.99 0.93-1.05 0.27 0.76
   Yes 716/1088 1.01 0.89-1.14 0.90
BMI
   Normal weight 2146/2665 1.00 0.93-1.07 0.97 0.50
   Overweight 1866/1918 0.99 0.91-1.07 0.77
   Obese 1284/1115 1.00 0.91-1.11 0.93
   Underweight 74/80 0.63 0.40-0.98 0.04
Site
   Colon 4037/6285 0.98 0.94-1.03 0.53 0.61c
   Rectum 1184/6285 0.98 0.91-1.06 0.65
Abbreviations: BMI, body mass index; CCFR, colon cancer family registry; CI, confidence interval; GRS, genetic risk score; OR, odds ratio per year. 
a all analyses adjusted for age, sex, study and principal components of genetic ancestry
b P  value calculated using likelihood ratio tests comparing the model with and without interaction term
c P  value for heterogeneity was obtained in case-only analysis of colon vs. rectal cancer
Combined estrogen-progesterone therapy 
Estrogen monotherapy
